In this edition of the Guidelines+ Monographs Series will delve into the medication alirocumab, marketed under the brand name Praluent® from Regeneron. Praluent (alirocumab) is a proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitor indicated to reduce the risk of myocardial infarction, stroke, and unstable angina requiring hospitalization in adults with established cardiovascular disease, as […]
Our latest edition of the Guidelines+ Monographs Series will delve into the medication irinotecan liposome injection, marketed under the brand name Onivyde® by Ipsen. Onivyde (irinotecan liposome injection) is a liposomal formulation of the topoisomerase I inhibitor irinotecan used in the treatment of pancreatic adenocarcinoma. Onivyde is indicated in combination with oxaliplatin, fluorouracil and leucovorin, […]
In recognition of National Influenza Vaccination Week (NIVW), our latest edition of the Guidelines+ Monographs Series will delve into the medication baloxavir marboxil, marketed under the brand name Xofluza® by Genentech. Xofluza is an influenza virus polymerase acidic (PA) endonuclease inhibitor indicated for the treatment of acute uncomplicated influenza in patients 5 years of age […]
In recognition of World AIDS Day 2024, our latest edition of the Guidelines+ Monographs Series will delve into the medication bictegravir, emtricitabine, and tenofovir alafenamide, marketed under the brand name Biktarvy® by Gilead Sciences, Inc. Biktarvy is a three-drug combination of bictegravir (BIC), a human immunodeficiency virus type 1 (HIV-1) integrase strand transfer inhibitor (INSTI), […]
Welcome to the latest edition of our Guidelines+ Monographs Series. In this installment, we will delve into the medication fluticasone furoate, umeclidinium, and vilanterol, marketed under the brand name Trelegy Ellipta by GlaxoSmithKline. Trelegy Ellipta is a combination of fluticasone furoate, an inhaled corticosteroid (ICS); umeclidinium, an anticholinergic; and vilanterol, a long-acting beta2-adrenergic agonist (LABA) indicated […]
Welcome to the latest edition of our Guidelines+ Monographs Series. In this installment, we will delve into the medication aflibercept, marketed under the brand name Eylea by Regeneron Pharmaceuticals, Inc. Eylea a is a vascular endothelial growth factor (VEGF) inhibitor indicated for the treatment of patients with Neovascular (Wet) Age-Related Macular Degeneration (AMD), Macular Edema […]
Welcome to the latest installment of our Guidelines+ Monographs Series. In this edition, we will delve into the medication vedolizumab, marketed under the brand name Entyvio by Takeda Pharmaceuticals. Entyvio is an integrin receptor antagonist indicated in adults for the treatment of moderately to severely active ulcerative colitis (UC) and moderately to severely active Crohn’s […]
Welcome to the latest edition of our Guidelines+ Monographs Series. In this installment, we will delve into the medication aripiprazole, marketed under the brand name Abilify Asimtufii by Otsuka Pharmaceutical Co., Ltd. Abilify Asimtufii (aripiprazole) is a long-acting injectable atypical antipsychotic for the treatment of schizophrenia and bipolar I disorder. It was initially approved in […]
Welcome to the newest installment of our Guidelines+ Monographs Series. Today, we will be exploring the medication naltrexone, specifically the injectable form marketed under the brand name Vivitrol by Alkermes, Inc. Vivitrol is an opioid antagonist that was first approved in 2006. It is prescribed for the treatment of alcohol dependence and to block the […]
Welcome to the latest edition of our Guidelines+ Monographs Series. In this installment, we will delve into the medication brexpiprazole, marketed under the brand name Rexulti by Otsuka America Pharmaceutical, Inc and Lundbeck LLC. Rexulti, an atypical antipsychotic, received initial approval in 2015. It is indicated for use as an adjunctive therapy to antidepressants for […]
In this installment of our Guidelines+ Monographs Series, we will delve into the medication olaparib, marketed under the brand name Lynparza by AstraZeneca. Lynparza, is a poly ADP ribose polymerase (PARP) inhibitor for the treatment of ovarian cancer, breast cancer, pancreatic cancer, and prostate cancer. It was initially approved in 2014. In the following sections, […]
Ovarian cancer, the 5th leading cause of cancer deaths in the U.S., is one of the deadliest gynecologic malignancies due to its mild early symptoms, often leading to late detection. This edition of our Guidelines+ Monograph series explores niraparib (brand name Zejula) from GlaxoSmithKline (GSK), a once-daily oral (PO) PARP inhibitor. It’s FDA-approved as a […]
The opioid crisis continues to be a major public health issue, with overdose rates still rising in many areas, particularly due to the increasing prevalence of synthetic opioids like fentanyl. This edition of our Guidelines+ Monograph series will be dedicated to International Overdose Awareness Day, a day on August 31st of each year dedicated to […]
In this edition of our Guidelines Monographs Series, we will be taking a look at AstraZeneca’s medication dapagliflozin, brand name Farxiga. Initially approved in 2014, Farxiga is a sodium-glucose cotransporter 2 (SGLT2) inhibitor, provided to individuals with diabetes, heart disease, or kidney disease to improve their outcomes. This Guidelines+ Monograph will take a deeper dive […]
In this edition of our Guidelines+ Monographs Series, we will be taking a look at Bristol-Myers Squibb’s medication apixaban, brand name Eliquis. Initially approved in 2012, Eliquis is a factor Xa inhibitor, an anticoagulant used to prevent stroke and systemic embolism in nonvalvular atrial fibrillation, and to treat deep vein thrombosis (DVT) and pulmonary embolism […]